Levofloxacin 500 mg once daily versus cefuroxime 250 mg twice daily in patients with acute exacerbations of chronic obstructive bronchitis: clinical efficacy and exacerbation-free interval

International Journal of Antimicrobial Agents

Volumn 30, Issue 1, 2007, Pages 52-59

  Petitpretz, Patrick ^a   Choné, Claudie ^b   Trémolières, François ^c  

^a CENTRE HOSPITALIER DE VERSAILLES   (France)

^b SANOFI   (France)

^c Hôpital François Quesnay   (France)

Author keywords

Acute exacerbation of chronic obstructive bronchitis; Antimicrobial efficacy; Cefuroxime; Exacerbation free interval; Levofloxacin

Indexed keywords

CEFUROXIME; CORTICOSTEROID; LEVOFLOXACIN;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONFUSION; CONGESTIVE HEART FAILURE; CONJUNCTIVITIS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DRUG EFFICACY; DRUG OVERDOSE; DRUG SAFETY; DYSPNEA; FEMALE; FOLLOW UP; HEADACHE; HUMAN; HYPERSENSITIVITY; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE CRAMP; MYALGIA; MYCOSIS; NAUSEA; PANIC; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RIGOR; TENDINITIS; TREATMENT OUTCOME;

AGED; BRONCHITIS, CHRONIC; CEFUROXIME; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; OFLOXACIN; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; TREATMENT OUTCOME;

EID: 34249900188     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2006.11.033     Document Type: Article

References (22)

1. Donaldson G.C., Seemungal T.A.R., Bhowmik A., and Wedzicha J.A. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 57 (2002) 847-852
2. Pietila M.P., and Thomas C.F. Inflammation and infection in exacerbations of chronic obstructive pulmonary disease. Semin Respir Infect 18 (2003) 9-16
3. Sin D.D., and Man S.F. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc 2 (2005) 8-11
4. Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest 117 Suppl 2 (2000) 380S-385S
5. Sethi S., Muscarella K., Evans N., Klingman K.L., Grant B.J., and Murphy T.F. Airway inflammation and etiology of acute exacerbations of chronic bronchitis. Chest 118 (2000) 1557-1565
6. Sethi S., Evans N., Grant B.J., and Murphy T.F. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 347 (2002) 465-471
7. Adams S.G., Melo J., Luther M., and Anzueto A. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest 117 (2000) 1345-1352
8. File T.M. New insights in the treatment by levofloxacin. Chemotherapy 50 Suppl. 1 (2004) 22-28
9. Shah P.M., Maesen F.P.V., Dolmann A., Vetter N., Fiss E., and Wesch R. Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis: results of a randomized, double-blind study. J Antimicrob Chemother 43 (1999) 529-539
10. Carbon C. Comparison of side effects of levofloxacin versus other fluoroquinolones. Chemotherapy 47 Suppl. 3 (2001) 9-14
11. De Abate C.A., Russel M., McElvaine P., et al. Safety and efficacy of oral levofloxacin versus cefuroxime. Respir Care 42 (1997) 206-213
12. Habib M.P., Gentry L.O., Rodriguez-Gomez G., et al. Multicentre, randomised study comparing efficacy and safety of oral levofloxacin and cefaclor in treatment of acute bacterial exacerbations of chronic bronchitis. Infect Dis Clin Pract 7 (1998) 101-109
13. Bartlett J.G., Ryan K.J., Smith T.F., and Wilson W.R. Laboratory diagnosis of lower respiratory tract infections. In: Washington J.A. (Ed). Cumitech 7A (1987), American Society for Microbiology, Washington, DC 1-18
14. Lode H., Eller J., Linnhoff A., and Ioanas M. Levofloxacin versus clarithromycin in COPD exacerbation: focus on exacerbation-free interval. Eur Respir J 24 (2004) 947-953
15. Wilson R., Allegra L., Huchon G., et al., MOSAIC Study Group. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 125 (2004) 953-964
16. Miravitlles M., and Torres A. Antibiotics in exacerbations of COPD: lessons from the past. Eur Respir J 24 (2004) 896-897
17. Van der Valk P., Monninkhof E., van der Palen J., Zielhuis G., van Herwaarden C., and Hendrix R. Clinical predictors of bacterial involvement in exacerbations of chronic obstructive pulmonary disease. Clin Infect Dis 39 (2004) 980-986
18. Chodosh S., Schreurs A., Siami G., et al. Efficacy of oral ciprofloxacin vs clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. Clin Infect Dis 27 (1998) 730-738
19. Chodosh S., McCarty J., Farkas S., et al. Randomized, double-blind study of ciprofloxacin and cefuroxime axetil for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. Clin Infect Dis 27 (1998) 722-729
20. Wilson R., Schentag J.J., Ball P., et al. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clin Ther 24 (2002) 639-652
21. Grassi C., Casali L., Curti E., et al. Efficacy and safety of short course (5-day) moxifloxacin vs 7-day ceftriaxone in the treatment of acute exacerbations of chronic bronchitis (AECB). J Chemother 14 (2002) 597-608
22. Wilson R., Jones P., Schahberg T., Arvis P., Duprat-Lomon I., Sagnier P.P., and MOSAIC Study Group. Antibiotic treatment and factors influencing short and long term outcomes of acute exacerbations of chronic bronchitis. Thorax 61 (2006) 337-342